CoreValve scores EU first for percutaneous aortic valve replacement
This article was originally published in Clinica
CoreValve has CE-marked for sale in Europe the first aortic valve replacement device that can be implanted percutaneously, thereby avoiding the need for open-heart surgery.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.